This week, Wheel rolled out a new AI-powered platform designed to provide patients with more holistic and seamless virtual care journeys. The platform, called Horizon, aims to help the startup’s customers rapidly scale virtual care programs to meet growing patient demand.
This month, Moon Surgical received FDA clearance for the commercial version of its Maestro surgical robot system. The system is designed to support surgeons and other operating room staff, specifically for the 18.8 million annual soft tissue surgical procedures not currently supported by available telerobotic systems.
This eBook, in collaboration with Care Logistics, details how hospitals and health systems can facilitate more effective decision-making by operationalizing elevated awareness.
Stitch PEO — a startup built at Redesign Health — officially launched and announced that it has raised $8.75 million in seed funding. The company is a professional employer organization for independent medical practices, designed to improve recruiting, hiring, onboarding, and other human resources processes.
CoraVie Medical, a startup developing an implantable continuous blood pressure monitor, recently won the medical devices track of MedCity News’ INVEST Pitch Perfect contest. The pre-revenue company’s remote management solution monitors for the early detection of dangerous blood pressure levels to prevent crises that could lead to heart attack, stroke, kidney failure or death.
The contest — which will include startup focusing on pediatric and teen behavioral health — will take place at Pegasus Park in Dallas on September 18. The deadline to submit applications is July 10, so apply today!
Here is a selection of recent executive hires, promotions, retirements and layoffs occurring across the healthcare industry.
At the Payer Insights sessions on Day 1 of ViVE 2024, a panel on prior authorization offered compelling insights from speakers who shared the positive developments in this area after years of mounting frustration. Speakers also shared challenges as they work with providers to figure out how policy developments and technology will work in practice.
CinRx Pharma’s most prominent spinout is CinCor Pharma, which was acquired by AstraZeneca last year. The startup creator will apply its new capital toward current programs and to expand to additional areas of unmet medical need.
Merck’s EyeBio acquisition brings a lead program ready for pivotal testing in diabetic macular edema. The therapy could pose competition to Eylea, the blockbuster Regeneron Pharmaceuticals eye drug.
Fem Therapeutics won the audience choice award in the Canadian PItch contest at MedCity INVEST in Chicago this week. It competed with Reach Orthopaedics , PragmaClin Research, and OPTT Health.
During a panel at MedCity News’ INVEST conference, venture capitalists shared some of their takes on today’s healthcare funding landscape — including their thoughts on AI and the industry’s slower investment pace.
The TSX Venture Exchange has a strong history of helping early-stage health and life sciences companies raise patient capital for research and development.
Centivo, a health plan that sells to self-funded employers, acquired virtual-first primary care startup Eden Health. With this acquisition, Centivo now serves more than 160 employers in all 50 states.
Saint Luke’s Mid America Heart Institute launched a new solution on its care platform to help patients who have AFib or are at risk of developing the condition. The program, which was developed with digital health startup Story Health, seeks to engage patients between clinic visits.
Watershed Health closed a $13.6 million funding round this week. The New Orleans-based company seeks to improve care coordination by connecting providers of all types across the healthcare system.
Johnson & Johnson’s Proteologix acquisition adds a pipeline of bispecific antibodies, including an experimental treatment for asthma and atopic dermatitis. It’s the latest M&A deal involving molecules addressing TSLP, a key signaling protein involved in inflammation.
Blackstone Life Sciences startup Uniquity Bio emerged from stealth with an in-licensed drug candidate that could treat a wide range of immunology and inflammation indications. The antibody's target puts it in competition with drugs from AstraZeneca, Pfizer, and Sanofi.